PUBLIC RELEASE DATE: <\/p>\n
22-Apr-2014 <\/p>\n
Contact: Vicki Cohn vcohn@liebertpub.com<\/a> 914-740-2100 Mary Ann Liebert, Inc.\/Genetic Engineering News<\/p>\n New Rochelle, NY, April 22, 2014Hemoglobin A1c is the standard measurement for assessing glycemic control over time in people with diabetes. Blood levels of A1c are typically measured every few months in a laboratory, but now researchers have developed a data-based model that accurately estimates A1c using self-monitored blood glucose (SMBG) readings, as described in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the DTT website at http:\/\/www.liebertpub.com\/dtt<\/a>. <\/p>\n In \"Accuracy and Robustness of Dynamical Tracking of Average Glycemia (A1c) to Provide Real-Time Estimation of Hemoglobin A1c Using Routine Self-Monitored Blood Glucose Data,\" authors Boris Kovatchev, PhD, Frank Flacke, PhD, Jochen Sieber, MD, and Marc Breton, PhD present the computer algorithm they developed based on a training data set drawn from 379 subjects and then evaluated for accuracy on an independent test data set. The authors propose that estimation of real-time A1c could increase individuals' motivation to improve diabetes control. <\/p>\n \"Patients are used to an A1c result from their doctor visits, and this study highlights simple estimated A1c values from SMBG data,\" says Satish Garg, MD, Editor-in-Chief of Diabetes Technology & Therapeutics and Professor of Medicine and Pediatrics at the University of Colorado Denver. \"This may become an important tool for improved patient self-management.\" <\/p>\n ### <\/p>\n About the Journal <\/p>\n Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of content and a sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website at http:\/\/www.liebertpub.com\/dtt<\/a>. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference. <\/p>\n About ATTD <\/p>\n <\/p>\n Read the original here: <\/p>\n Routine blood glucose measurements can accurately estimate hemoglobin A1c in diabetes<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" PUBLIC RELEASE DATE: 22-Apr-2014 Contact: Vicki Cohn vcohn@liebertpub.com<\/a> 914-740-2100 Mary Ann Liebert, Inc.\/Genetic Engineering News New Rochelle, NY, April 22, 2014Hemoglobin A1c is the standard measurement for assessing glycemic control over time in people with diabetes. Blood levels of A1c are typically measured every few months in a laboratory, but now researchers have developed a data-based model that accurately estimates A1c using self-monitored blood glucose (SMBG) readings, as described in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the DTT website at http:\/\/www.liebertpub.com\/dtt<\/a> Continue reading